TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Kringen, Pedro ^a   Wang, Yun ^a,b   Dumeaux, Vanesa ^a,c   Nesland, Jahn M ^a   Kristensen, Gunnar ^a   Borresen Dale, Anne Lise ^a,b   Dorum, Anne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; FORMALDEHYDE; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; FOLLOW UP; FOUNDER EFFECT; GEL ELECTROPHORESIS; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HEREDITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CARCINOMA; PENETRANCE; PROTECTION; SOMATIC MUTATION; SURVIVAL RATE; TISSUE FIXATION; DNA SEQUENCE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; NORWAY; ONSET AGE; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; EXONS; FEMALE; FOUNDER EFFECT; GENE DELETION; GENES, BRCA1; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NORWAY; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 27644578246     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-134     Document Type: Article

References (43)

1. Cancer in Norway 1998. [http://www.kreftregisteret.no/]
2. Engeland A, Haldorsen T, Tretli S, Hakulinen T, Horte LG, Luostarinen T, Magnus K, Schou G, Sigvaldason H, Storm HH: Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries. APMIS Suppl 1993, 38:1-124.
3. Zweemer RP, Verheijen RH, Menko FH, Gille JJ, van Diest PJ, Coebergh JW, Shaw PA, Jacobs IJ, Kenemans P: Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 82(2):151-153.
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71.
5. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378(6559):789-792.
6. Boyd J: Molecular genetics of hereditary ovarian cancer. Oncology (Huntingt) 1998, 12(3):399-406; discussion 409-310, 413.
7. Lynch HT, Watson P, Lynch JF, Conway TA, Fili M: Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer 1993, 71(2 Suppl):573-581.
8. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995, 57(6):1457-1462.
9. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J : Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62(3):676-689.
10. Dorum A, Heimdal K, Hovig E, Inganas M, Moller P: Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am J Hum Genet 1999, 65(3):671-679.
11. Dorum A, Moller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Trope CG, van der Hout AH: A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Eur J Cancer 1997, 33(14):2390-2392.
12. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL: Clinical and pathological features of ovarian cancer in women with germ- line mutations of BRCA1. N Engl J Med 1996, 335(19):1413-1416.
13. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002, 20(2):463-466.
14. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97(9):2187-2195.
15. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998, 16(2):397-404.
16. Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS: Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 2002, 8(5):1196-1202.
17. Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL: Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 1998, 78(3):375-381.
18. Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BA, Friedman LS: Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999, 25(2):91-96.
19. Tworek H, Peng R, Fetzer S, Werness BA, Piver MS, Allen HJ, DiCioccio RA: Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. Cancer Genet Cytogenet 1999, 112(2):105-118.
20. Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA: The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001, 7(4):831-838.
21. Rhei E, Bogomolniy F, Federici MG, Maresco DL, Offit K, Robson ME, Saigo PE, Boyd J: Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 1998, 58(15):3193-3196.
22. Schorge JO, Muto MG, Lee SJ, Huang LW, Welch WR, Bell DA, Keung EZ, Berkowitz RS, Mok SC: BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000, 60(5):1361-1364.
23. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC: p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994, 86(20):1549-1551.
24. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE: P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001, 194(1):68-75.
25. Ozalp S, Yalcin OT, Minsin TH: Expression of p53 in epithelial ovarian cancer. Int J Gynaecol Obstet 2000, 71(3):277-278.
26. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A: Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997, 11(10):1226-1241.
27. Sourvinos G, Spandidos DA: Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 1998, 245(1):75-80.
28. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale AL, Kristensen GB: TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 2004, 90(3):678-685.
29. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM: Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 2004, 24(1):21-34.
30. Andersen TI, Borresen AL, Moller P: A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet 1996, 59(2):486-487.
31. Dorum A, Hovig E, Trope C, Inganas M, Moller P: Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer 1999, 35(5):779-781.
32. Borg A, Dorum A, Heimdal K, Maehle L, Hovig E, Moller P: BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations. Dis Markers 1999, 15(1-3):79-84.
33. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215.
34. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL: Mutation Screening of the TP53 Gene by Temporal Temperature Gradient Gel Electrophoresis. Methods Mol Biol 2004, 291:207-216.
35. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19(6):607-614.
36. Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuck A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH: Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999, 52(5):372-375.
37. Zweemer RP, Verheijen RH, Coebergh JW, Jacobs IJ, van Diest PJ, Gille JJ, Skates S, Menko FH, Ten Kate LP, Kenemans P: Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 2001, 98(2):219-223.
38. Goldgar DE, Reilly PR: A common BRCA1 mutation in the Ashkenazim. Nat Genet 1995,11(2):113-114.
39. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, Burke MM, Sullivan D, Macpherson P, Karran P: Defective DNA Mismatch Repair in Acute Myeloid Leukemia/Myelodysplastic Syndrome After Organ Transplantation. Blood 2004.
40. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995, 14(1):71-75.
41. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer [see comments]. J Natl Cancer Inst 1999, 91(4):339-346.
42. Bjorge T, Engeland A, Sundfor K, CG. T: Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 1998, 77(7):777-781.
43. Bjorge T, Engeland A, Hansen S, Trope CG: Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 1998, 75(5):663-670.